Roles of cMET/ErbB3 activation and overexpression in the development or resistance to EGFR inhibitors in NSCLC patients.

被引：0
|
作者：
Ahn, Myung-Ju
Park, Silvia
Sun, Jong-Mu
Ahn, Jin Seok
Park, Keunchil
Langley, Emma J.
Kim, Phillip Sangwook
Singh, Sharat
Lockton, Steve
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea
[3] Prometheus Labs Inc, San Diego, CA USA
[4] Prometheus Therapeut & Diagnost, San Diego, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11113
引用
收藏
页数：1
相关论文
共 50 条
  • [1] ERBB3 as predictor of response and target for overcoming resistance to EGFR inhibitors in NSCLC
    Witta, S
    Hirsch, F
    Coldren, C
    Helfrich, B
    Zeng, C
    Barón, A
    Bunn, P
    Varella-Garcia, M
    LUNG CANCER, 2005, 49 : S66 - S66
  • [2] Endocrine resistance in breast cancer: new roles for ErbB3 and ErbB4
    Sutherland, Robert L.
    BREAST CANCER RESEARCH, 2011, 13 (03):
  • [3] Endocrine resistance in breast cancer: new roles for ErbB3 and ErbB4
    Robert L Sutherland
    Breast Cancer Research, 13
  • [4] Mathematical modeling and analysis of ErbB3 and EGFR dimerization process for the gefitinib resistance
    Itano, Keiko
    Ito, Takeshi
    Kawasaki, Shuji
    Murakami, Yoshinori
    Suzuki, Takashi
    JSIAM LETTERS, 2018, 10 : 33 - 36
  • [5] Increased ErbB3 and EGFR activity mediate lapatinib resistance in prostate cancer
    Jathal, Maitreyee K.
    Steele, Thomas M.
    Mooso, Benjamin A.
    D'Abronzo, Leandro S.
    Siddiqui, Salma
    Drake, Christiana
    Ghosh, Paramita M.
    CANCER RESEARCH, 2014, 74 (19)
  • [6] ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma
    De Bacco, Francesca
    Orzan, Francesca
    Erriquez, Jessica
    Casanova, Elena
    Barault, Ludovic
    Albano, Raffaella
    D'Ambrosio, Antonio
    Bigatto, Viola
    Reato, Gigliola
    Patane, Monica
    Pollo, Bianca
    Kuesters, Geoffrey
    Dell'Aglio, Carmine
    Casorzo, Laura
    Pellegatta, Serena
    Finocchiaro, Gaetano
    Comoglio, Paolo M.
    Boccaccio, Carla
    CELL REPORTS, 2021, 36 (04):
  • [7] YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC
    Ghiso, Elena
    Migliore, Cristina
    Ciciriello, Vito
    Morando, Elena
    Petrelli, Annalisa
    Corso, Simona
    De Luca, Emmanuele
    Gatti, Gaia
    Volante, Marco
    Giordano, Silvia
    NEOPLASIA, 2017, 19 (12): : 1012 - 1021
  • [8] MEHD7945A, an EGFR/ErbB3 dual specific antibody, overcomes acquired resistance to EGFR inhibitors in head and neck and lung tumors
    Huang, Shyhmin
    Li, Chunrong
    Sliwkowski, Mark X.
    Harari, Paul M.
    CANCER RESEARCH, 2011, 71
  • [9] Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant
    Frogne, Thomas
    Benjaminsen, Rikke V.
    Sonne-Hansen, Katrine
    Sorensen, Boe S.
    Nexo, Ebba
    Laenkholm, Anne-Vibeke
    Rasmussen, Louise M.
    Riese, David J., II
    de Cremoux, Patricia
    Stenvang, Jan
    Lykkesfeldt, Anne E.
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 114 (02) : 263 - 275
  • [10] Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant
    Thomas Frogne
    Rikke V. Benjaminsen
    Katrine Sonne-Hansen
    Boe S. Sorensen
    Ebba Nexo
    Anne-Vibeke Laenkholm
    Louise M. Rasmussen
    David J. Riese
    Patricia de Cremoux
    Jan Stenvang
    Anne E. Lykkesfeldt
    Breast Cancer Research and Treatment, 2009, 114
12345